Add on Study on Δ9-THC Treatment for Posttraumatic Stress Disorders (PTSD)

Phase 4

• Conditions: Posttraumatic Stress Disorders
• Interventions: Drug: Tetrahydrocannabinol; Other: Placebo

• Registration Number: NCT00965809
• Lead Sponsor: Hadassah Medical Organization

Brief Summary

Stress Disorder (PTSD) is a chronic and debilitating anxiety disorder which is widespread in every social level and is very prevalent in outpatient and inpatient settings.

A recent open-label study showed that the synthetic cannabinoid receptor agonist Nabilone had beneficial effects abolishing or greatly reducing nightmares that persisted in spite of treatment with conventional PTSD medications. Furthermore, a big number of patients suffering from chronic PTSD report using smoked marijuana because its tranquilizing effect and sleep quality improvement. According to clinical and epidemiological data different derivates from the cannabis plant are illegally and pervasively consumed by PTSD patients in order to reduce distress.

The aim of the proposed study is to broaden the previous observations and to measure the extent to which Δ 9-THC will bring to significant improvement on the full spectrum of PTSD symptoms.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2009-08-25
• Study First Submitted QC: 2009-08-25
• Study First Posted: 2009-08-26
• Study Start: 2009-10
• Status Verified: 2012-09
• Primary Completion: 2012-10
• Last Update Submitted: 2012-10-28
• Last Update Posted: 2012-10-30
• Study Completion: 2013-04

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 70

Inclusion Criteria

• Outpatients between the 19-60 years of age with a diagnosis of PTSD.
• Women must not be currently pregnant and must use a reliable method of contraception for the duration of the study.
• Subjects must be on stable medication (4 weeks minimum) for their PTSD (symptomatic despite current treatment), must be able to provide written informed consent, must be able adequately understand and comply with the study's instructions and protocol .

Exclusion Criteria

• Those not meeting the inclusion criteria and those not able to give informed consent.
• Women who are currently pregnant or nursing.
• Those at immediate risk of harming self or others; those who have a clinically significant medical illness or other significant psychiatric illness;
• currently abusing alcohol or drugs;
• currently being treated with an investigational medication or medication that is contraindicated with cannabinoids;
• have a known allergy to cannabis-based products.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
ACTIVE THC	Tetrahydrocannabinol	Subjects will take 5MG of THC in 6 drops of olive oil orally.
Placebo	Placebo	Subjects will take 6 drops of olive oil orally twice a day from an identical vial than those in the active arm

Primary Outcome Measures

Name	Time	Method
Clinician Administered PTSD Scale	Baseline and end o ftreatment

Secondary Outcome Measures

Name	Time	Method
Nightmare Frequency Questionaire Score	Baseline Weeks 3 &6 (EOS)

Trial Locations

Locations (1)

Hadassah Medical Organization; 🇮🇱 Jerusalem, Israel